Talbot George H
Cerexa, Inc., 1751 Harbor Bay Parkway, Alameda, CA 94502, USA.
Expert Rev Anti Infect Ther. 2008 Feb;6(1):39-49. doi: 10.1586/14787210.6.1.39.
The emergence of new human pathogens and increasing antimicrobial resistance in well-established pathogens are critical public health concerns. Unfortunately, the pipeline of new antimicrobial candidates remains remarkably lean for molecules active against increasingly problematic Gram-negative bacterial pathogens, such as Acinetobacter baumannii and Pseudomonas aeruginosa. Although a number of new anti-Gram-negative antibacterial agents are likely to be introduced soon for clinical use, they will not represent a quantum leap in our ability to effectively treat these human pathogens of great concern. New classes of antimicrobials with novel mechanisms of action and new approaches to increasing the effectiveness of traditional antimicrobials are urgently needed. Renewed research and development efforts must become a priority, lest we fall further behind in our therapeutic initiatives.
新出现的人类病原体以及已确认病原体中日益增加的抗菌药物耐药性是重大的公共卫生问题。不幸的是，对于针对日益棘手的革兰氏阴性菌病原体（如鲍曼不动杆菌和铜绿假单胞菌）具有活性的分子而言，新抗菌候选药物的研发渠道仍然非常有限。尽管有一些新型抗革兰氏阴性菌抗菌药物可能很快会被引入临床使用，但它们并不会在我们有效治疗这些备受关注的人类病原体的能力上带来质的飞跃。迫切需要具有新型作用机制的新型抗菌药物类别以及提高传统抗菌药物有效性的新方法。必须重新将研发工作作为优先事项，以免我们在治疗举措上进一步落后。
